🇺🇸 FDA
Patent

US 11472875

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11472875 (Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/05, A61K47/6849